MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Personalis, Inc.

< Previous 1 2 3 4 Next >
Personalis to Announce Third Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Second Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce Second Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Dr. Kenneth J. Widder Joins Personalis Board of Directors
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports First Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce First Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Appoints Christopher Hall as Chief Executive Officer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
From Personalis, Inc.
Via Business Wire
Tickers MRNA PSNL
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces CEO Retirement and Transition
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Cancer Assay NeXT Personal Ranks #1 on The Scientist’s Top 10 Innovations of 2022
From Personalis, Inc.
Via Business Wire
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story